These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35604958)

  • 21. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.
    Carroll JB; Deik A; Fossale E; Weston RM; Guide JR; Arjomand J; Kwak S; Clish CB; MacDonald ME
    PLoS One; 2015; 10(8):e0134465. PubMed ID: 26295712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased translation as a novel pathogenic mechanism in Huntington's disease.
    Creus-Muncunill J; Badillos-Rodríguez R; Garcia-Forn M; Masana M; Garcia-Díaz Barriga G; Guisado-Corcoll A; Alberch J; Malagelada C; Delgado-García JM; Gruart A; Pérez-Navarro E
    Brain; 2019 Oct; 142(10):3158-3175. PubMed ID: 31365052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
    Brown TB; Bogush AI; Ehrlich ME
    Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
    Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
    J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
    Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
    Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
    Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
    Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset.
    Nair A; Johnson EB; Gregory S; Osborne-Crowley K; Zeun P; Scahill RI; Lowe J; Papoutsi M; Palminteri S; Rutledge RB; Rees G; Tabrizi SJ
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2021 Sep; 6(9):910-918. PubMed ID: 33795209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
    van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
    Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rac1 Activity Is Modulated by Huntingtin and Dysregulated in Models of Huntington's Disease.
    Tousley A; Iuliano M; Weisman E; Sapp E; Zhang N; Vodicka P; Alexander J; Aviolat H; Gatune L; Reeves P; Li X; Khvorova A; Ellerby LM; Aronin N; DiFiglia M; Kegel-Gleason KB
    J Huntingtons Dis; 2019; 8(1):53-69. PubMed ID: 30594931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin.
    Galvan L; Francelle L; Gaillard MC; de Longprez L; Carrillo-de Sauvage MA; Liot G; Cambon K; Stimmer L; Luccantoni S; Flament J; Valette J; de Chaldée M; Auregan G; Guillermier M; Joséphine C; Petit F; Jan C; Jarrige M; Dufour N; Bonvento G; Humbert S; Saudou F; Hantraye P; Merienne K; Bemelmans AP; Perrier AL; Déglon N; Brouillet E
    Brain; 2018 May; 141(5):1434-1454. PubMed ID: 29534157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
    Xifró X; García-Martínez JM; Del Toro D; Alberch J; Pérez-Navarro E
    J Neurochem; 2008 Jun; 105(5):1596-612. PubMed ID: 18221365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.
    Estrada-Sánchez AM; Burroughs CL; Cavaliere S; Barton SJ; Chen S; Yang XW; Rebec GV
    J Neurosci; 2015 Mar; 35(10):4440-51. PubMed ID: 25762686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A developmental component to Huntington's disease.
    Ratié L; Humbert S
    Rev Neurol (Paris); 2024 May; 180(5):357-362. PubMed ID: 38614929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease.
    Francelle L; Galvan L; Gaillard MC; Guillermier M; Houitte D; Bonvento G; Petit F; Jan C; Dufour N; Hantraye P; Elalouf JM; De Chaldée M; Déglon N; Brouillet E
    Hum Mol Genet; 2015 Mar; 24(6):1563-73. PubMed ID: 25398949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of normal huntingtin function: new developments in Huntington's disease research.
    Cattaneo E; Rigamonti D; Goffredo D; Zuccato C; Squitieri F; Sipione S
    Trends Neurosci; 2001 Mar; 24(3):182-8. PubMed ID: 11182459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.